Cargando…

Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9

BACKGROUND—: Transient preceding brief ischemia provides potent cardioprotection against subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that transient short-term hypertrophic stimulation would induce the expression of hypertrophy regression genes and render the hear...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xuan, Wu, Bing, Zhao, Jing, Zeng, Zhi, Xuan, Wanling, Cao, Shiping, Huang, Xiaobo, Asakura, Masanori, Xu, Dingli, Bin, Jianping, Kitakaze, Masafumi, Liao, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415966/
https://www.ncbi.nlm.nih.gov/pubmed/25820336
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013789
_version_ 1782369161136046080
author Wei, Xuan
Wu, Bing
Zhao, Jing
Zeng, Zhi
Xuan, Wanling
Cao, Shiping
Huang, Xiaobo
Asakura, Masanori
Xu, Dingli
Bin, Jianping
Kitakaze, Masafumi
Liao, Yulin
author_facet Wei, Xuan
Wu, Bing
Zhao, Jing
Zeng, Zhi
Xuan, Wanling
Cao, Shiping
Huang, Xiaobo
Asakura, Masanori
Xu, Dingli
Bin, Jianping
Kitakaze, Masafumi
Liao, Yulin
author_sort Wei, Xuan
collection PubMed
description BACKGROUND—: Transient preceding brief ischemia provides potent cardioprotection against subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that transient short-term hypertrophic stimulation would induce the expression of hypertrophy regression genes and render the heart resistant to subsequent hypertrophic stress, and slow the progression to heart failure, as well. METHODS AND RESULTS—: Cardiomyocyte hypertrophy was induced in mice by either transverse aortic constriction or an infusion of phenylephrine, and in neonatal rat ventricular cardiomyocytes by norepinephrine exposures. In the preconditioning groups, hypertrophic stimulation was provided for 1 to 7 days and then withdrawn for several days by either aortic debanding or discontinuing phenylephrine or norepinephrine treatment, followed by subsequent reexposure to the hypertrophic stimulus for the same period as in the control group. One or 6 weeks after transverse aortic constriction, the heart weight/body weight ratio was lower in the preconditioning group than in the control group, whereas the lung weight/body weight ratio was significantly decreased 6 weeks after transverse aortic constriction. Similar results were obtained in mice receiving phenylephrine infusion and neonatal rat ventricular cardiomyocytes stimulated with norepinephrine. Both mRNA and protein expression of S100A8 and S100A9 showed significant upregulation after the removal of hypertrophic stimulation and persisted for 6 weeks in response to reimposition of transverse aortic constriction. The treatment with recombinant S100A8/A9 inhibited norepinephrine-induced myocyte hypertrophy and reduced the expression of calcineurin and NFATc3, but the silencing of S100A8/A9 prevented such changes. CONCLUSIONS—: Preconditioning with prohypertrophic factors exerts an antihypertrophic effect and slows the progression of heart failure, indicating the existence of the phenomenon for hypertrophic preconditioning.
format Online
Article
Text
id pubmed-4415966
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-44159662015-05-11 Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 Wei, Xuan Wu, Bing Zhao, Jing Zeng, Zhi Xuan, Wanling Cao, Shiping Huang, Xiaobo Asakura, Masanori Xu, Dingli Bin, Jianping Kitakaze, Masafumi Liao, Yulin Circulation Original Articles BACKGROUND—: Transient preceding brief ischemia provides potent cardioprotection against subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that transient short-term hypertrophic stimulation would induce the expression of hypertrophy regression genes and render the heart resistant to subsequent hypertrophic stress, and slow the progression to heart failure, as well. METHODS AND RESULTS—: Cardiomyocyte hypertrophy was induced in mice by either transverse aortic constriction or an infusion of phenylephrine, and in neonatal rat ventricular cardiomyocytes by norepinephrine exposures. In the preconditioning groups, hypertrophic stimulation was provided for 1 to 7 days and then withdrawn for several days by either aortic debanding or discontinuing phenylephrine or norepinephrine treatment, followed by subsequent reexposure to the hypertrophic stimulus for the same period as in the control group. One or 6 weeks after transverse aortic constriction, the heart weight/body weight ratio was lower in the preconditioning group than in the control group, whereas the lung weight/body weight ratio was significantly decreased 6 weeks after transverse aortic constriction. Similar results were obtained in mice receiving phenylephrine infusion and neonatal rat ventricular cardiomyocytes stimulated with norepinephrine. Both mRNA and protein expression of S100A8 and S100A9 showed significant upregulation after the removal of hypertrophic stimulation and persisted for 6 weeks in response to reimposition of transverse aortic constriction. The treatment with recombinant S100A8/A9 inhibited norepinephrine-induced myocyte hypertrophy and reduced the expression of calcineurin and NFATc3, but the silencing of S100A8/A9 prevented such changes. CONCLUSIONS—: Preconditioning with prohypertrophic factors exerts an antihypertrophic effect and slows the progression of heart failure, indicating the existence of the phenomenon for hypertrophic preconditioning. Lippincott Williams & Wilkins 2015-04-28 2015-04-28 /pmc/articles/PMC4415966/ /pubmed/25820336 http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013789 Text en © 2015 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDervis (https://creativecommons.org/licenses/by-nc-nd/3.0/) License, which permits use, distribution, and reproduction in any medium, provided that the Contribution is properly cited, the use is non-commercial, and no modifications or adaptations are made.
spellingShingle Original Articles
Wei, Xuan
Wu, Bing
Zhao, Jing
Zeng, Zhi
Xuan, Wanling
Cao, Shiping
Huang, Xiaobo
Asakura, Masanori
Xu, Dingli
Bin, Jianping
Kitakaze, Masafumi
Liao, Yulin
Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
title Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
title_full Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
title_fullStr Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
title_full_unstemmed Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
title_short Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
title_sort myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of s100a8/a9
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415966/
https://www.ncbi.nlm.nih.gov/pubmed/25820336
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013789
work_keys_str_mv AT weixuan myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT wubing myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT zhaojing myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT zengzhi myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT xuanwanling myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT caoshiping myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT huangxiaobo myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT asakuramasanori myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT xudingli myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT binjianping myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT kitakazemasafumi myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9
AT liaoyulin myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9